Pentetreotide
Pentetreotide is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| octreoscan | New Drug Application | 2022-02-21 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9572 | Indium in-111 pentetreotide, diagnostic, per study dose, up to 6 millicuries |
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 3 | 1 | — | 1 | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | 1 | |
| Medulloblastoma | D008527 | — | 1 | — | — | — | 1 | ||
| Somatostatinoma | D013005 | — | 1 | — | — | — | 1 | ||
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | 1 | — | — | — | 1 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | 1 | — | — | — | — | 1 | ||
| Lung neoplasms | D008175 | C34.90 | 1 | — | — | — | — | 1 | |
| Pheochromocytoma | D010673 | 1 | — | — | — | — | 1 | ||
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 | ||
| Melanoma | D008545 | 1 | — | — | — | — | 1 | ||
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Neuroendocrine carcinoma | D018278 | 1 | — | — | — | — | 1 | ||
| Paraneoplastic syndromes | D010257 | 1 | — | — | — | — | 1 | ||
| Islet cell adenoma | D007516 | EFO_0007331 | D13.7 | 1 | — | — | — | — | 1 |
| Langerhans-cell histiocytosis | D006646 | C96.6 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PENTETREOTIDE |
| INN | pentetreotide |
| Description | Pentetreotide is a protein pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Protein |
| Drug class | peptides: inhibition of growth hormone release |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108757 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | G083B71P98 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,189 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
49 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more